{"nctId":"NCT04328961","briefTitle":"Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)","startDateStruct":{"date":"2020-03-31","type":"ACTUAL"},"conditions":["COVID-19","Corona Virus Infection","SARS (Severe Acute Respiratory Syndrome)","SARS-CoV-2"],"count":943,"armGroups":[{"label":"Ascorbic Acid","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Ascorbic Acid"]},{"label":"Hydroxychloroquine","type":"EXPERIMENTAL","interventionNames":["Drug: Hydroxychloroquine Sulfate"]}],"interventions":[{"name":"Hydroxychloroquine Sulfate","otherNames":["HCQ arm"]},{"name":"Ascorbic Acid","otherNames":["Placebo arm"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent\n* Willing and able to provide informed consent\n* Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection or who is currently being assessed for COVID-19. Close contact defined as:\n\n  1. Household contact (i.e., residing with the index case in the 14 days prior to index diagnosis)\n  2. Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)\n* Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection) to the index case\n* Body weight \\< 100 kg (self-reported)\n* Access to device and internet for Telehealth visits\n\nExclusion Criteria:\n\n* Known hypersensitivity to HCQ or other 4-aminoquinoline compounds\n* Currently hospitalized\n* Symptomatic with subjective fever, cough, or sore throat\n* Current medications exclude concomitant use of HCQ\n* Concomitant use of other anti-malarial treatment or chemoprophylaxis\n* History of retinopathy of any etiology\n* Psoriasis\n* Porphyria\n* Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes \\< 1500) or thrombocytopenia (\\< 100 K)\n* Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen\n* Known liver disease\n* Known long QT syndrome\n* Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs, or planned use during the study period","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection","description":"Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection","description":"Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Participant-reported Adverse Events","description":"Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Had COVID-19 Disease","description":"Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":422},"commonTop":["Diarrhea, abdominal discomfort, or vomiting","Nausea or upset stomach","Skin reaction/rash","Neurologic reaction: irritability, dizziness, or vertifgo","Headache"]}}}